By David Bautz, PhD
NASDAQ:BCLI
READ THE FULL BCLI RESEARCH REPORT
Business Update
Topline Data from Phase 3 ALS Trial Before End of November 2020
BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is currently conducting a Phase 3 clinical trial of NurOwn in patients with amyotrophic lateral sclerosis (ALS) (NCT03280056). A total of 200 patients were randomized 1:1 to receive NurOwn or placebo in the randomized, double blind, placebo controlled, multi-dose trial. Cells were extracted once from each patient prior to treatment, with all administrations of NurOwn derived from the same extraction of cells due to a cryopreservation process the company developed for long-term storage of mesenchymal stem cells (MSC). Just as with the companys prior studies, there was a 3-month run-in period prior to the first treatment with two additional NurOwn treatments occurring two and four months following the first treatment. The company is focusing the trial on faster-progressing ALS patients since those patients demonstrated superior outcomes in the Phase 2 trial of NurOwn. The primary outcome of the trial is the ALSFRS-R score responder analysis and we now anticipate topline results before the end of November 2020.
Update on Phase 2 Progressive Multiple Sclerosis Trial
BrainStorm is currently conducting a Phase 2 clinical trial of NurOwn in patients with progressive multiple sclerosis (MS) (NCT03799718). The trial is an open label, single arm study that is enrolling patients with progressive MS with Expanded Disability Status Scale (EDSS) scores of 3.0 6.5. The primary endpoint of the study is the safety and tolerability of three doses of NurOwn with secondary endpoints examining the timed 25-foot walking speed or 9-hole peg test (both validated MS clinical outcome assessments) along with paired cerebrospinal fluid (CSF) and blood biomarker analysis. The National Multiple Sclerosis Society awarded the company a $0.5 million grant to help fund the study.
The trial is now fully enrolled and we anticipate dosing to be completed for all patients by the end of 2020. While the company had previously considered performing an interim analysis, since topline data would be available soon after an interim analysis could be performed the company has decided against performing an interim analysis and will instead report topline data for all 20 patients when it becomes available.
NurOwn Derived Exosomes Show Promise in Preclinical ARDS Study
On July 23, 2020, BrainStorm announced the successful completion of the first milestone in developing an exosome-based platform for the treatment of severe acute respiratory distress syndrome (ARDS) caused by COVID-19. Exosomes are small vesicles (30-150 nm) that are secreted by all cell types. Exosomes from mesenchymal stem cells (MSCs), from which NurOwn is derived, can penetrate into deep tissues and deliver various bioactive molecules. In addition, they can be delivered both intravenously or intratracheally.
BrainStorm conducted a preclinical study of MSC-derived exosomes in a mouse model of lipopolysaccharide (LPS)-induced ARDS. Treatment with intratracheally administered exosomes resulted in a statistically significant improvement in various lung functions, including functional lung recovery and decreased lung damage, as judged by the lung disease severity score (P=0.03). In addition, they led to a reduction in a number of pro-inflammatory cytokines. Lastly, exosomes derived from MSC-NTF cells were superior to exosomes derived from nave MSC from the same donor.
We anticipate the results being submitted to a peer reviewed journal for publication and the company is currently deciding whether to initiate a clinical trial program in COVID-19 patients with ARDS.
Financial Update
On August 5, 2020, BrainStorm announced financial results for the second quarter of 2020. As anticipated, the company did not report any revenues during the second quarter of 2020. Net R&D expenses for the second quarter of 2020 were $5.7 million, compared to $3.6 million for the second quarter of 2019. The increase was primarily due to an increase in payroll and stock-based compensation and a decrease in support from the Israel Innovation Authority (IIA) and California Institute for Regenerative Medicine (CIRM) along with a decrease in costs related to the Phase 3 and Phase 2 clinical trials. Excluding participation from the IIA and CIRM, R&D expenses were $6.0 million in the second quarter of 2020, compared to $6.5 million in the second quarter of 2019. G&A expenses for the second quarter of 2020 were $1.7 million, compared to $1.3 million in the second quarter of 2019. The increase was primarily due to increased payroll and stock-based compensation.
The company exited the second quarter of 2020 with approximately $16.2 million in cash, cash equivalents, and short-term investments. Subsequent to the end of the quarter, the company raised gross proceeds of approximately $13.7 million from the $50 million ATM facility entered into in March 2020 through the sale of 945,082 shares at an average price of $14.48 per share. In addition, the company raised gross proceeds of approximately $6.3 million from the exercise of warrants. We estimate that the company currently has approximately $35 million in cash, cash equivalents, and short-term investments.
As of July 31, 2020, the company had approximately 31.5 million shares outstanding and, when factoring in warrants and stock options, a fully diluted share count of approximately 37.0 million.
Conclusion
The countdown is on to the topline data release for the Phase 3 ALS trial, with those results expected before the end of November 2020. Even with the great run the stock has had since its recent lows in March 2020, we continue to view the shares as undervalued as we currently forecast peak sales for NurOwn of >$1 billion in ALS, >$500 million in MS, and >$2 billion in Alzheimers disease. We recently made a slight change to our model, in which we decreased the discount rate from 17% to 13%, and combined with the recent financing activity has resulted in an increase to our valuation to $33 per share.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCHtoreceive our articles and reports emailed directly to you each morning. Please visit ourwebsitefor additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer HERE.
See more here:
BCLI: Phase 3 ALS Data Expected by the End of November 2020 - Zacks Small Cap Research
- 100 plus years of stem cell research20 years of ISSCR - PMC - March 26th, 2024
- Stem Cell Science and Human Research Studies Ahead of Cargo Arrival - NASA Blogs - February 18th, 2024
- Stem cell research project to launch into space - Fox Weather - January 24th, 2024
- Breakthrough in cancer research opening up stem cell therapy to more people. How you can get involved - 69News WFMZ-TV - January 20th, 2024
- Stem Cell Research Heading to the ISS on Axiom Mission 3 - ISS National Lab - January 18th, 2024
- No, Rep. Steve Scalise Didn't Vote Against Stem Cell Research From Which He Is Now Benefiting - The Dispatch - January 12th, 2024
- Applications are open for the Maryland Stem Cell Research Fund - Technical.ly - January 4th, 2024
- Global Stem Cell Therapy Market to Reach USD 928.6 Million by 2031: Says Allied Market Research - Yahoo Finance - November 19th, 2023
- Current state of stem cell-based therapies: an overview - PMC - November 3rd, 2023
- Dynamic Stem Cell Therapy Uncovers Research in Advance Regenrative Medicine - Yahoo Finance - November 3rd, 2023
- Research Fellow (Aging and Cancer Stem Cell Laboratory ... - Times Higher Education - October 15th, 2023
- Qkine Collaborates with the Cambridge Stem Cell Institute to Facilitate Same-Day Access to Key Research Products for Researchers at the Cambridge... - September 27th, 2023
- Stem cells: a comprehensive review of origins and emerging clinical ... - September 25th, 2023
- Stem Cell Research and Communicating Science | GBH - GBH News - September 20th, 2023
- Stem cell research reveals the earliest stages of a human life - SBS News - September 10th, 2023
- Stem Cell Therapy Market Size 2023 | Innovative Research Methodologies with Emerging Trends and Opportuni - Benzinga - September 10th, 2023
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market Research, Current Trends, Key Industry Play - Benzinga - September 8th, 2023
- Stem Cell Therapy Market 2023 Business Statistics and Research ... - The Knox Student - August 28th, 2023
- Autologous Stem Cell Based Therapies Market Analysis, Research ... - Chatfield News-Record - July 19th, 2023
- Global Stem Cell Market Projected to Reach $14 Bn by 2028: Ken Research - Yahoo Finance - July 11th, 2023
- Theradaptive Awarded Manufacturing Assistance Grant by the Maryland Stem Cell Research Fund - Benzinga - July 10th, 2023
- Bionano Announces Presentation of OGM Utility Across Stem Cell Therapy Applications at the International Society for Stem Cell Research (ISSCR) Annual... - June 19th, 2023
- Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023... - June 17th, 2023
- Induced Pluripotent Stem Cell (iPSC) Global Market Report 2023: Effective Research Programs Hold Key in Roll Out of Advanced iPSC Treatments - Yahoo... - June 17th, 2023
- Lung and heart stem cell research paves way for new COVID-19 treatments - Medical Xpress - June 14th, 2023
- Toxicology PhD student cultivating giant leaps in stem cell research ... - June 4th, 2023
- Harvard Stem Cell Institute (HSCI) - May 26th, 2023
- Findings may lead to improved insulin-secreting cells derived from stem ... - May 26th, 2023
- Cell Press: Stem Cell Reports - May 26th, 2023
- Stem cell research could enable blood to be made in other parts of the body - Medical Xpress - May 26th, 2023
- Construction of myocardial patch with mesenchymal stem cells and poly ... - May 22nd, 2023
- Cedars-Sinai to Send Stem Cells to the Space Station to Aid in the ... - May 22nd, 2023
- researchers expand human blood stem cells | Institute for Stem Cell ... - May 22nd, 2023
- A Look Inside Stem Cells Helps Create Personalized Regenerative ... - May 17th, 2023
- Exclusive Research Report on Msenchymal Stem Cell and Exosome Diagnostics and Therapies Market to Witness Comp - openPR - May 17th, 2023
- The Future of Stem Cell Research: Master of Science in ... - The Daily | Case Western Reserve University - May 10th, 2023
- Exclusive Research Report on Stem Cell Therapy for Diabetes and ... - Digital Journal - May 9th, 2023
- Aging melanocyte stem cells and gray hair | National Institutes of ... - May 5th, 2023
- Mouse hair turns gray when certain stem cells get stuck - May 5th, 2023
- Science-First Skincare Company Michal Morrison Secures Exclusive World-Wide License of Proprietary STEM6 Molecule, Supported by Over 25 Years of... - May 5th, 2023
- BioCentriq and panCELLa execute research agreement to study stem cell-derived Natural Killer cell expansi - Benzinga - May 3rd, 2023
- Hair turning gray? Study finds a stem cell 'glitch' may be the cause - May 1st, 2023
- Elevai Labs Announces Research Grant Award and Partnership to Better Characterize the 'Payload' of ELEVAI's Stem Cell-derived Exosomes - Yahoo Finance - April 27th, 2023
- Why does hair turn gray? A new study says 'stuck' stem cells may ... - NPR - April 27th, 2023
- Study advances understanding of how melanocyte stem cells work to color ... - April 21st, 2023
- Stem cell research and therapy legislation to be replaced, says ... - Bahamas Tribune - April 21st, 2023
- Stem Cell Research (journal) - Wikipedia - April 21st, 2023
- Scientists Are About to Try to Create Stem Cells in Space - April 21st, 2023
- Stem Cell Research & Therapy | Articles - BioMed Central - April 16th, 2023
- Stem Cell Junk Yards Reveal a New Clue About Aging | WIRED - April 16th, 2023
- Global Stem Cells Market Research Report 2023: Implications - April 16th, 2023
- Stem cell research can help people with hard- | EurekAlert! - April 16th, 2023
- University Of Edinburgh's stem cell research gets funding boost - India Education Diary - April 14th, 2023
- Two major stem cell research projects supported with more than ... - University of California, Santa Cruz - April 8th, 2023
- Cancer detection predicts tumors before they form: discovery - March 29th, 2023
- Stem cell therapy: a potential cure for hearing loss? - March 29th, 2023
- Turkey's Only Stem Cell Production Application and Research Center - Expat Guide Turkey - March 24th, 2023
- Stem Cell Research Article, Embryonic Cells Information, Cell Therapy ... - March 24th, 2023
- Scientists create mice with cells from 2 males for 1st time - March 19th, 2023
- QBRI concludes stem cells symposium - Gulf Times - March 17th, 2023
- 2020 California Proposition 14 - Wikipedia - March 17th, 2023
- Stem Cell Reports | Journal | ScienceDirect.com by Elsevier - March 17th, 2023
- Stem cell therapy MSC-NP found to ease inflammatory activity of brain ... - March 12th, 2023
- Stem Cell Research | Office of Research Compliance | SIU - March 12th, 2023
- Heart disease study shows hope for stem cell treatment - March 4th, 2023
- Stem cells drive antler regeneration | Science - March 4th, 2023
- Stem Cell Research: Argumentative Essay - Free Essay Example - Edubirdie - March 4th, 2023
- Stem Cell Research | Thermo Fisher Scientific - US - March 4th, 2023
- Stem cell controversy - Wikipedia - February 28th, 2023
- National Institutes of Health grant funds interdisciplinary ... - February 27th, 2023
- Research Associate in Cancer Stem Cell Research job with ... - Times Higher Education - February 25th, 2023
- Pioneering Stem Cell Research Conference at The Aga Khan ... - The Aga Khan University - February 25th, 2023
- Scientists grapple with ethics of stem cell research - STAT - February 17th, 2023
- Research Associate in Stem Cell Neurobiology job with KINGS ... - Times Higher Education - January 30th, 2023
- Stem cells: past, present, and future | Stem Cell Research & Therapy ... - January 12th, 2023
- Edu Thesis & Essay: Stem cell research outline top writers online! - January 12th, 2023
- Stem Cell Biology Research Program | Johns Hopkins Institute for Cell ... - January 5th, 2023
- Stem cell population identified is vital for bone regeneration: Research - ThePrint - January 5th, 2023
- Leading scientist 'blown away' by UAE advances in stem cell research - The National - December 15th, 2022
- The Stem Cell Assay Market Is Set To Grow At A 20% Annual Rate, Due To The High Prevalence Of Chronic Diseases As Per The Business Research Company's... - December 13th, 2022
Recent Comments